NICE does not recommend Merck’s lung cancer drug
2 March 2017 | By Niamh Marriott, Digital Editor
NICE has published draft guidance which does not recommend Keytruda, also known as pembrolizumab, for untreated PD-L1-positive metastatic lung cancer...